Autori: Moldoveanu Elena , Serban M, Marta DS, Serban I, Huica R

Editorial: Biomarkers, Vol. 16, No. 7, p.587–589, 2011.

Rezumat:

Background: A significant proportion of heart failure (HF) patients have preserved ejection fraction (EF). Considering that inflammation and oxidative stress are involved in HF evolution, we investigated lipoprotein-associated phospholipase A2 (LpPLA2), an enzyme involved in these pathophysiologic processes in relation to EF.

Methods and results: The study included 208 HF patients and 20 healthy controls. HF patients with preserved EF (HFpEF) represented 42.31% of all HF patients. LpPLA2 activity was significantly increased in HF patients when compared with controls and was higher in HFpEF than in HF with reduced EF patients (HFrEF). The incidence of left ventricular hypertrophy was higher in HFpEF than in HFrEF (EF < 50). Conclusion: Confirming its role as a marker of vascular inflammation, LpPLA2 seems to be a biomarker constantly correlated with HF, regardless of etiology. Elevated plasma values of LpPLA2 in HFpEF are consistent with the exacerbated inflammatory status. Read More: http://informahealthcare.com/doi/abs/10.3109/1354750X.2011.611597

Cuvinte cheie: Inflammation, lipoprotein-associated phospholipase A2, heart failure with preserved ejection fraction

URL: http://informahealthcare.com/doi/abs/10.3109/1354750X.2011.611597